BioCentury
ARTICLE | Clinical News

E6201: Phase I data

May 31, 2010 7:00 AM UTC

In an open-label, dose-escalating Phase I trial in 25 patients with advanced solid tumors, E6201 led to 1 case of stable disease for >10 months in a patient with metastatic ocular melanoma and 1 parti...